IP Library Patent Application 11363911
Patent Application
App. No. 11/363,911

Use of pigmented retinal epithelial cells for creation of an immune privilege site

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/363,911
Abstract

The present invention relates to a novel in vivo method for creation of a localized immunosuppressive environment in tissue. The method involves the transplanting of pigmented retinal epithelial cells into a mammal thereby producing a localized immunosuppressive environment. The transplanted pigmented retinal epithelial cells may also be used to produce therapeutic proteins or other biologically active molecules that may be useful in treatment of diseases.

Claims (13)

1 - 24 . (canceled)

25 . A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells, a non-RPE cell population, and a pharmaceutically acceptable carrier, wherein said non-RPE cell population comprises insulin-producing β cells.

26 . The composition of claim 25 wherein said insulin-producing β cells are pancreatic islet of Langerhans cells.

27 . A compartmentalized kit adapted to receive a first container adapted to contain retinal pigment epithelial (RPE) cells and a second container adapted to contain a non-RPE cell population, wherein the non-RPE cell population comprises insulin-producing β cells.

28 . The compartmentalized kit according to claim 27 wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.

29 . The composition of claim 25 wherein said RPE cells are attached to a matrix.

30 . The composition of claim 25 wherein cells of said non-RPE cell population are attached to a matrix.

31 . An article of manufacture, comprising:

a packaging material;

retinal pigment epithelial (RPE) cells containing within said packaging material;

a non-RPE cell population contained within said packaging material, wherein the non-RPE cell population comprises insulin-producing β cells; and

wherein said packaging material contains a label that indicates that said RPE cells can be used for facilitating survival of an allogeneic graft of the non-RPE cell population in a mammal.

32 . The article of manufacture according to claim 31 , wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Feb 1, 2018
From: OXFORD FINANCE LLC
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 044802/0909 →
RELEASE OF SECURITY INTEREST Recorded Feb 1, 2018
From: OXFORD FINANCE CORPORATION
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 044803/0064 →
RELEASE OF SECURITY INTEREST Recorded Apr 6, 2011
From: OXFORD FINANCE CORPORATION
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 026084/0908 →
SECURITY AGREEMENT Recorded Dec 23, 2009
From: TITAN PHARMACEUTICALS, INC.
To: OXFORD FINANCE CORPORATION
Reel/Frame 023699/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2006
From: THERACELL, INC.
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 017538/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2006
From: ALLEN, RICHARD C.; CORNFELDT, MICHAEL L.; KIDWELL, WILLIAM R.
To: THERACELL, INC.
Reel/Frame 017529/0705 →